论文部分内容阅读
目的观察胺碘酮联合丹参酮ⅡA磺酸钠治疗急性心肌梗死并发心房颤动(房颤)的效果。方法 98例急性心肌梗死并发房颤患者按照随机数字表法分为试验组和对照组,对照组静脉滴注胺碘酮150 mg·d~(-1);试验组静脉滴注胺碘酮150 mg·d~(-1)联合静脉滴注丹参酮ⅡA磺酸钠150 mg·d~(-1),2组均治疗10d。用酶联免疫吸附法检测治疗前后血清C反应蛋白(CRP)变化情况,并记录2组患者缺血事件发生情况。结果治疗前,试验组与对照组的血清CRP分别为(24.63±10.58),(24.57±11.12)mg·L~(-1)(P>0.05)。治疗后,试验组与对照组的血清CRP分别为(13.21±10.25),(21.52±13.22)mg·L~(-1)(P<0.05),试验组疗效较好。试验组患者心力衰竭、房颤复发率、病死率均低于对照组患者(P<0.05)。结论胺碘酮联合丹参酮ⅡA磺酸钠治疗心肌梗死并发房颤效果显著且较安全。
Objective To observe the effect of amiodarone combined with tanshinone Ⅱ A sulfonate in the treatment of atrial fibrillation in patients with acute myocardial infarction. Methods A total of 98 patients with acute myocardial infarction complicated by atrial fibrillation were randomly divided into experimental group and control group. The control group received amiodarone 150 mg · d ~ (-1) intravenously. Amiodarone 150 mg · d ~ (-1) combined with intravenous infusion of tanshinone Ⅱ A sulfonate 150 mg · d -1, both groups were treated for 10 days. The changes of serum C-reactive protein (CRP) before and after treatment were detected by enzyme-linked immunosorbent assay (ELISA), and the occurrence of ischemic events were recorded in two groups. Results Before treatment, the serum CRP in test group and control group were (24.63 ± 10.58) and (24.57 ± 11.12) mg · L -1, respectively (P> 0.05). After treatment, the serum CRP levels in the test group and the control group were (13.21 ± 10.25) and (21.52 ± 13.22) mg · L -1, respectively (P <0.05). Heart failure, atrial fibrillation recurrence rate and mortality in the experimental group were lower than those in the control group (P <0.05). Conclusions Amiodarone combined with sodium tanshinone Ⅱ A in the treatment of acute myocardial infarction complicated by atrial fibrillation is more effective and safer.